Recurrence of appendix tumor: case report and literature update

Abstract

Herein, we report a case of appendix adenocarcinoma who presented with a recurrence 8 years after the initial diagnosis. A 54-year-old male underwent appendectomy in 2009. The pathology revealed a 1.7 cm diameter low grade mucinous carcinoid tumor. Any additional treatment was not recommended for patient other than appendectomy. The patient was admitted with the symptoms of ileus at 8 years after surgery and then underwent to right hemicolectomy in 2017. On histopathological examination of the specimen revealed a Goblet cell adenocarcinoid tumor, arising from iliocecal valv with pericolorectal tissue invasion of 5 cm in diameter. Lymph-node metastases were found in 16 dissected lymph nodes. The patient was initiated to treat with combined capecitabine and oxaliplatin chemotherapy. There is no clear evidence to support the superiority of any particular chemotherapy regimen for adjuvant treatment of appendix tumors. In this regard more studies are needed to use combined regimens. 

Keywords

• Appendiceal,adenocarcinoma,chemotherapy

References

1. 1. Connor SJ, Hanna GB, Frizelle FA. Appendiceal tumors: retrospective clinicopathologic analysis of appendiceal tumors from 7,970 appendectomies. Dis Colon Rectum 1998;41:75-80.
2. 2. Moertel CG, Weiland LH, Nagorney DM, Dockerty MB. Carcinoid tumor of the appendix: treatment and prognosis. N Engl J Med 1987;317:1699-701.
3. 3. Mahteme H, Sugarbaker PH. Treatment of peritoneal carcinomatosis from adenocarcinoid of appendiceal origin. Br J Surg 2004;91:1168-73.
4. 4. Cortina R, McCormick J, Kolm P, Perry RR. Management and prognosis of adenocarcinoma of the appendix. Dis Colon Rectum 1995;38:848-52.
5. 5. Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol 2005;89:151-60.
6. 6. Boudreaux JP, Klimstra DS, Hassan MM, Woltering EA, Jensen RT, Goldsmith SJ, et al;. North American Neuroendocrine Tumor Society (NANETS). The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. Pancreas 2010;39:753-66.
7. 7. Pape UF, Perren A, Niederle B, Gross D, Gress T, Costa F, et al. Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 2012;95:135-56.
8. 8. Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller T, et al. Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012;95:157-76.

9. 9. Butler JA, Houshiar A, Lin F, Wilson SE. Goblet cell carcinoid of the appendix. Am J Surg 1994;168:685-7.
10. 10. Garin L, Corbinais S, Boucher E, Blanchot J, Le Guilcher P, Raoul JL. Adenocarcinoid of the appendix vermiformis: complete and persistent remission after chemotherapy (folfox) of a metastatic case. Dig Dis Sci 2002;47:2760-2.
11. 11. Ito H, Osteen RT, Bleday R, Zinner MJ, Ashley SW, Whang EE. Appendiceal adenocarcinoma: long-term outcomes after surgical therapy. Dis Colon Rectum 2004;47:474-80.
12. 12. Turaga KK, Pappas S, Gamblin TC. Right hemicolectomy for mucinous adenocarcinoma of the appendix: just right or too much? Ann Surg Oncol 2013;20:1063-7.
13. 13. Proulx GM, Willett CG, Daley W, Shellito PC. Appendiceal carcinoma: patterns of failure following surgery and implications for adjuvant therapy. J Surg Oncol 1997;66:51-3.
14. 14. Sugarbaker PH. Managing the peritoneal surface component of gastrointestinal cancer. Part 2. Perioperative intraperitoneal chemotherapy. Oncology (Williston Park). 2004;18:207-19.
15. 15. Shapiro JF, Chase JL, Wolff RA, Lambert LA, Mansfield PF, Overman MJ, et al. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience. Cancer 2010;116:316-22.